ReviewNature reviews. Disease primers2023
Cryptococcal meningitis.
Review in Nature reviews. Disease primers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 109 citations in OpenAlex.
- Esculetin exhibits antifungal effects againstVirulence · 2026Article
- Article
- The AP-1 adaptor complex is required for cell surface modifications and the survival ofInfection and immunity · 2026Article
- Subunits of adaptor protein complex-1 make distinct contributions to the virulence ofInfection and immunity · 2026Article
- Article
- The persistent challenge of meningitis in the vaccine era: a three-decade longitudinal analysis of residual burden in the United States.Infection · 2026Article
- Article
- Trehalose-6-phosphate synthase promotes thermotolerance by governing glycolytic flux inbioRxiv : the preprint server for biology · 2026Article
- Cellular and molecular responses ofMicrobiology spectrum · 2026Article
- Patterns of Infectious Disease Identified in Clinical Autopsy at a South African Tertiary Care Setting: A 10-Year Retrospective Study.Diseases (Basel, Switzerland) · 2026Article
- Acetylation and accessibility ofCell surface (Amsterdam, Netherlands) · 2026Article
- Cryptococcal meningitis in an immunocompetent host: acute bilateral sensorineural hearing loss with normal intracranial pressure.BMC neurology · 2026Article
- Review
- Fungal meningoencephalitis caused byMedical mycology case reports · 2026Article
- Article
- One-pot recombinase polymerase amplification and CRISPR/Cas12a assay for Cryptococcus neoformans.Applied microbiology and biotechnology · 2026Article
- Cryptococcus neoformans Meningitis in a Patient With Epidermolysis Bullosa and Rheumatoid Arthritis.Cureus · 2026Article
- Article
- Integrative Transcriptomic and Systems Biology Analyses IdentifyMicroorganisms · 2026Article
- Admission D-Dimer for Early Risk Stratification of in-Hospital Mortality in Adults with Non-HIV Cryptococcal Meningitis: A Retrospective Cohort Study.Infection and drug resistance · 2026Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
Abstract
Cryptococcus neoformans and Cryptococcus gattii species complexes cause meningoencephalitis with high fatality rates and considerable morbidity, particularly in persons with deficient T cell-mediated immunity, most commonly affecting people living with HIV. Whereas the global incidence of HIV-associated cryptococcal meningitis (HIV-CM) has decreased over the past decade, cryptococcosis still accounts for one in five AIDS-related deaths globally due to the persistent burden of advanced HIV disease. Moreover, mortality remains high (~50%) in low-resource settings. The armamentarium to decrease cryptococcosis-associated mortality is expanding: cryptococcal antigen screening in the serum and pre-emptive azole therapy for cryptococcal antigenaemia are well established, whereas enhanced pre-emptive combination treatment regimens to improve survival of persons with cryptococcal antigenaemia are in clinical trials. Short courses (≤7 days) of amphotericin-based therapy combined with flucytosine are currently the preferred options for induction therapy of cryptococcal meningitis. Whether short-course induction regimens improve long-term morbidity such as depression, reduced neurocognitive performance and physical disability among survivors is the subject of further study. Here, we discuss underlying immunology, changing epidemiology, and updates on the management of cryptococcal meningitis with emphasis on HIV-associated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.